Applying Molecular and Functional Genomics to Identify Biomarkers for Diagnosing and Treating Cancer

应用分子和功能基因组学来识别诊断和治疗癌症的生物标志物

• 批准号: 10018811
• 负责人: Kiranmai Gumireddy
• 金额: $ 13.82万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-16 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10018811
• 关键词: Adoption; Area; Award; Bioinformatics; Biological Assay; Biological Markers; Biopsy; Cancer Patient; Cells; Cellular biology; Clinical; Collaborations; Diagnosis; Ensure; Funding; Gene Expression Profile; Genetic Markers; Genomics; Glioblastoma; Goals; Individual; Industry; Journals; Knowledge; Legal patent; Malignant Neoplasms; Malignant neoplasm of lung; Methods; Molecular; Molecular Biology; Molecular Biology Techniques; Nature; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Paper; Patients; Peripheral Blood Mononuclear Cell; Plasma; Protocols documentation; Publications; Publishing; RNA; RNA Editing; Research; Research Personnel; Research Project Grants; Risk; Role; Sampling; Screening for cancer; Specialist; Techniques; Technology; The Wistar Institute; Translational Research; Tumor Antigens; Work; base; biobank; blood-based biomarker; career; circulating biomarkers; design; effective therapy; experience; functional genomics; genomic data; improved; interest; nano-string; novel; operation; personalized medicine; success; tumorigenesis

SUMMARY This application will support an exceptional Research Specialist who is essential to the scientific direction, operation, and enhancement of a productive research group. The Research Specialist and Unit Director have worked together since 2009, closely since 2017. The major goal of the Unit Director’s group is to develop inexpensive, non-invasive methods that can identify individuals who are at risk of non-small cell lung cancer and use the information obtained to improve therapy. As part of this effort, the Research Specialist is responsible for collecting and maintaining The Wistar Institute biorepository of 3,350 non-small cell lung cancer patient samples, including PBMC, PAXgene, and plasma. The Director’s group also manages Genomics and Bioinformatics Cores, which support ~15 NCI-funded research projects. Last, the Unit Director and Research Specialist collaborate with other Wistar investigators and industry to: identify a gene expression signature that can subclassify glioblastoma, characterize a potential new tumor antigen generated by the fusion of 2 LNC- RNAs, and understand the role of A-to-I RNA editing in metastasis. The Research Specialist has expertise in cell and molecular biology and extensive experience in multiple genomics and cell biology techniques. She also has a strong interest in translational research and has been able to apply the knowledge generated to design more effective therapies for lung cancer and glioblastoma. She is first author on 17 of the 26 papers she has published and on 9 of the 17 papers published during her 12-year tenure at Wistar. Many are in highly ranked journals including Nature Cell Biology, PNAS, EMBO, and Cell. She is listed on 5 U.S. patents. The Research Specialist’s expertise in a wide variety of molecular biology techniques is critical for the success of all main projects. It makes her ideally suited to conduct the studies on developing lung cancer genetic and biomarker signatures using genomic based assays; it also enables her to identify areas where improvements/changes are needed and independently develop protocols to improve the variety of assays employed. Since the Showe lab has been the primary developer of new genomics technologies for adoption by the Genomics Core, the Research Specialist’s background is essential for being able to develop these new platforms, including TCR-seq, the assessment of various platforms for single cell genomics, and the implementation of various NanoString technologies. For most work, the Research Specialist is the primary interface with Bioinformatics, ensuring that genomic data is correctly interpreted for analysis. The Research Specialist is essential not only for completing the proposed work of the next five years, but also for identifying new directions and new research and clinical collaborations. In summary, this award will allow the Research Specialist to continue making significant contributions to identifying circulating biomarkers for early cancer detection and to understanding the mechanisms of metastasis and oncogenesis. It will advance the identification of circulating biomarkers for lung cancer, support multiple NCI-funded groups via the Genomics Core, and enhance novel collaborations.

概括 该应用程序将支持一位对科学方向至关重要的杰出研究专家 产品研究小组的操作和增强。研究专家兼单位主任 自2009年以来，自2017年以来密切合作。该单位董事小组的主要目标是发展 廉价的非侵入性方法可以识别有非小细胞肺癌和 使用获得的信息来改善治疗。作为这项工作的一部分，研究专家负责 收集和维护3,350个非小细胞肺癌患者的Wistar Institute生物座 样品，包括PBMC，Paxgene和等离子体。导演小组还管理基因组学和 生物信息学核心，支持约15个NCI资助的研究项目。最后，单位主管和研究 专家与其他Wistar调查员和行业合作，以确定一个基因表达签名 可以亚分类化胶质母细胞瘤，表征由2个LNC-融合产生的潜在的新肿瘤抗原 RNA，并了解A-to-I RNA编辑在转移中的作用。研究专家有专业知识 细胞和分子生物学以及多种基因组学和细胞生物学技术的丰富经验。她也是 对翻译研究有浓厚的兴趣，并且能够将生成的知识应用于设计 肺癌和胶质母细胞瘤的更有效疗法。她是她的26篇论文中的17篇作者 在她在Wistar的12年任期期间发表的17篇论文中发表并发表。许多人排名很高 包括自然细胞生物学，PNA，EMBO和细胞在内的期刊。她被列为美国5项专利。研究 专家在各种分子生物学技术方面的专业知识对于所有主要主要的成功至关重要 项目。这使她非常适合进行有关发展肺癌遗传和生物标志物的研究 使用基于基因组测定的签名；它还使她能够确定改进/更改的领域 需要并独立开发协议，以改善所使用的各种测定法。由于秀实验室 一直是基因组核心采用新基因组技术的主要开发者 专家的背景对于能够开发这些新平台至关重要，包括TCR-Seq， 评估单细胞基因组学的各种平台以及各种纳米串的实施 技术。对于大多数工作，研究专家是生物信息学的主要接口，以确保 正确解释了基因组数据进行分析。研究专家不仅对于完成 未来五年的拟议工作，但也用于确定新的方向，新的研究和临床 协作。总而言之，该奖项将使研究专家能够继续发挥重要作用 为识别循环生物标志物的早期癌症检测和理解的贡献 转移和肿瘤发生的机制。它将推动识别肺循环生物标志物 癌症，通过基因组核心支持多个NCI资助的小组，并增强了新颖的合作。